CLINIMIX E SOLUTION

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

METHIONINE; L-ISOLEUCINE; L-VALINE; HISTIDINE; L-THREONINE; SODIUM ACETATE; POTASSIUM PHOSPHATE DIBASIC; SODIUM CHLORIDE; MAGNESIUM CHLORIDE; DEXTROSE; L-LEUCINE; L-PHENYLALANINE; LYSINE (L-LYSINE HYDROCHLORIDE); TRYPTOPHAN; L-ALANINE; L-ARGININE; L-PROLINE; SERINE; GLYCINE; L-TYROSINE

Inapatikana kutoka:

BAXTER CORPORATION

ATC kanuni:

B05BA10

INN (Jina la Kimataifa):

COMBINATIONS

Kipimo:

200MG; 300MG; 290MG; 240MG; 210MG; 205MG; 261MG; 58.5MG; 24MG; 10G; 365MG; 280MG; 290MG; 90MG; 1.04G; 575MG; 340MG; 250MG; 515MG; 20MG

Dawa fomu:

SOLUTION

Tungo:

METHIONINE 200MG; L-ISOLEUCINE 300MG; L-VALINE 290MG; HISTIDINE 240MG; L-THREONINE 210MG; SODIUM ACETATE 205MG; POTASSIUM PHOSPHATE DIBASIC 261MG; SODIUM CHLORIDE 58.5MG; MAGNESIUM CHLORIDE 24MG; DEXTROSE 10G; L-LEUCINE 365MG; L-PHENYLALANINE 280MG; LYSINE (L-LYSINE HYDROCHLORIDE) 290MG; TRYPTOPHAN 90MG; L-ALANINE 1.04G; L-ARGININE 575MG; L-PROLINE 340MG; SERINE 250MG; GLYCINE 515MG; L-TYROSINE 20MG

Njia ya uendeshaji:

INTRAVENOUS

Vitengo katika mfuko:

2000ML

Dawa ya aina:

Ethical

Eneo la matibabu:

REPLACEMENT PREPARATIONS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 2050850018; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

1999-03-10

Tabia za bidhaa

_Product Monograph Master Template _
_Template Date: September 2020 _
_CLINIMIX E (Blend C) _
_Page 1 of 31_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
CLINIMIX E
Amino Acids with Electrolytes in Dextrose Injection
5% Amino Acids (Blend C) with Electrolytes in 10% Dextrose Injection
5% Amino Acids (Blend C) with Electrolytes in 16.6% Dextrose Injection
Solution for Infusion, Intravenous
Intravenous Nutritive Supplements
Baxter Corporation
Mississauga, Ontario
L5N 0C2
Date of Initial Authorization:
DEC 31, 1993
Date of Revision:
MAR 31, 2022
Submission Control Number: 256758
Baxter, Clinimix, Clarity and Travasol are registered trademarks of
Baxter International Inc.
_ _
_Product Monograph Master Template _
_Template Date: September 2020 _
_CLINIMIX E (Blend C) _
_Page 2 of 31_
RECENT MAJOR LABEL CHANGES
6 Warnings and Precautions
04/2020
3 Dosage and Administration
08/2020
6 Warnings and Precautions
08/2020
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
....